Of these, CAIX, integrins, PLOD2, CXCR4, EGFRvIII (that induces up-regulation of MMP-2, MMP-9, and integrin β3 in a HIF-1α/hypoxia dependent manner), HSP90 (which induces hypoxic activation of EphA2) and to a limited extent TF have been shown to be potentially promising targets for GBM treatment. This evidence concerns the gene CXCR4 and glioblastoma.